A standard operating procedure for King’s ALS clinical staging

References

• Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain J Neurol. 2012;135:847–52.
   Google Scholar
• Chio A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:38–44.
   PubMed Web of Science ®Google Scholar
• Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C, UK-MND LiCALS, et al. Comparison of the King’s and MiToS staging systems for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:227–32.
   PubMed Web of Science ®Google Scholar
• Ferraro D, Consonni D, Fini N, Fasano A, Del Giovane C, Emilia Romagna Registry for ALSG, et al. Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study. Eur J Neurol. 2016;23:1426–32.
   PubMed Web of Science ®Google Scholar
• Jones AR, Jivraj N, Balendra R, Murphy C, Kelly J, Thornhill M, et al. Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:285–91.
   PubMed Web of Science ®Google Scholar
• Oh J, An JW, Oh SI, Oh KW, Kim JA, Lee JS, et al. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:202–8.
   PubMed Web of Science ®Google Scholar
• Pinto S, de Carvalho M. Comparison of slow and forced vital capacities on ability to predict survival in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:528–33.
   PubMed Web of Science ®Google Scholar
• Balendra R, Jones A, Jivraj N, Steen IN, Young CA, Shaw PJ, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry. 2015;86:45–9.
   PubMed Web of Science ®Google Scholar
• Tramacere I, Dalla Bella E, Chio A, Mora G, Filippini G, Lauria G, et al. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:1118–5.
   Web of Science ®Google Scholar
• Bella ED, Tramacere I, Antonini G, Borghero G, Capasso M, Caponnetto C, et al. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial). BMJ Open. 2017;7:e015434.
   PubMed Web of Science ®Google Scholar
• Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416–22.
   PubMed Web of Science ®Google Scholar
• Trojsi F, Caiazzo G, Di Nardo F, Fratello M, Santangelo G, Siciliano M, et al. High angular resolution diffusion imaging abnormalities in the early stages of amyotrophic lateral sclerosis. J Neurol Sci. 2017;380:215–22.
   PubMed Web of Science ®Google Scholar
• Floeter MK, Danielian LE, Braun LE, Wu T. Longitudinal diffusion imaging across the C9orf72 clinical spectrum. J Neurol Neurosurg Psychiatry. 2018;89:53–60.
   PubMed Web of Science ®Google Scholar
• Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74:525–32.
   PubMed Web of Science ®Google Scholar
• Puentes F, Topping J, Kuhle J, van der Star BJ, Douiri A, Giovannoni G, et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:274–8.
   PubMed Web of Science ®Google Scholar
• Lee J, Baek H, Kim SH, Park Y. Association between estimated total daily energy expenditure and stage of amyotrophic lateral sclerosis. Nutrition. 2017;33:181–6.
   PubMed Web of Science ®Google Scholar
• Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.
   PubMed Web of Science ®Google Scholar
• Ehinger JK, Morota S, Hansson MJ, Paul G, Elmer E. Mitochondrial dysfunction in blood cells from amyotrophic lateral sclerosis patients. J Neurol. 2015;262:1493–503.
   PubMed Web of Science ®Google Scholar
• Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586–90.
   PubMed Web of Science ®Google Scholar
• Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416–38.
   PubMed Web of Science ®Google Scholar
• Burke T, Pinto-Grau M, Lonergan K, Bede P, O’Sullivan M, Heverin M, et al. A cross-sectional population-based investigation into behavioral change in amyotrophic lateral sclerosis: subphenotypes, staging, cognitive predictors, and survival. Ann Clin Transl Neurol. 2017;4:305–17.
   PubMed Web of Science ®Google Scholar
• Trojsi F, Santangelo G, Caiazzo G, Siciliano M, Ferrantino T, Piccirillo G, et al. Neuropsychological assessment in different King’s clinical stages of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:228–35.
   PubMed Web of Science ®Google Scholar
• Christopher JC, Lonergan K, Chiwera T, Booth T, Chandran S, Colville S, et al. ALS specific cognitive and behaviour changes associated with advancing disease stage in ALS. Neurology. 2018;91:e1370–e80.
   PubMed Web of Science ®Google Scholar
• Lule D, Bohm S, Muller HP, Aho-Ozhan H, Keller J, Gorges M, et al. Cognitive phenotypes of sequential staging in amyotrophic lateral sclerosis. Cortex. 2018;101:163–71.
   PubMed Web of Science ®Google Scholar
• Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:9–14.
   PubMed Web of Science ®Google Scholar
• Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS functional rating scale. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:279–84.
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–10.
   PubMed Web of Science ®Google Scholar
• Sedgwick P. Limits of agreement (Bland-Altman method). BMJ. 2013;346:f1630.
   PubMedGoogle Scholar